338 related articles for article (PubMed ID: 25603859)
1. Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia.
Goldstein ME; Anderson VM; Pillai A; Kydd RR; Russell BR
Int J Neuropsychopharmacol; 2015 Jan; 18(6):. PubMed ID: 25603859
[TBL] [Abstract][Full Text] [Related]
2. Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study.
Iwata Y; Nakajima S; Plitman E; Caravaggio F; Kim J; Shah P; Mar W; Chavez S; De Luca V; Mimura M; Remington G; Gerretsen P; Graff-Guerrero A
Biol Psychiatry; 2019 Apr; 85(7):596-605. PubMed ID: 30389132
[TBL] [Abstract][Full Text] [Related]
3. Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.
Plitman E; Chavez S; Nakajima S; Iwata Y; Chung JK; Caravaggio F; Kim J; Alshehri Y; Chakravarty MM; De Luca V; Remington G; Gerretsen P; Graff-Guerrero A
Psychiatry Res Neuroimaging; 2018 Mar; 273():16-24. PubMed ID: 29414127
[TBL] [Abstract][Full Text] [Related]
4. Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity.
Shah P; Plitman E; Iwata Y; Kim J; Nakajima S; Chan N; Brown EE; Caravaggio F; Torres E; Hahn M; Chakravarty MM; Remington G; Gerretsen P; Graff-Guerrero A
J Psychiatr Res; 2020 May; 124():151-158. PubMed ID: 32169688
[TBL] [Abstract][Full Text] [Related]
5. Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data.
Merritt K; McGuire PK; Egerton A; ; Aleman A; Block W; Bloemen OJN; Borgan F; Bustillo JR; Capizzano AA; Coughlin JM; De la Fuente-Sandoval C; Demjaha A; Dempster K; Do KQ; Du F; Falkai P; Galinska-Skok B; Gallinat J; Gasparovic C; Ginestet CE; Goto N; Graff-Guerrero A; Ho BC; Howes OD; Jauhar S; Jeon P; Kato T; Kaufmann CA; Kegeles LS; Keshavan M; Kim SY; Kunugi H; Lauriello J; Liemburg EJ; Mcilwain ME; Modinos G; Mouchlianitis ED; Nakamura J; Nenadic I; Öngür D; Ota M; Palaniyappan L; Pantelis C; Plitman E; Posporelis S; Purdon SE; Reichenbach JR; Renshaw PF; Russell BR; Sawa A; Schaefer M; Shungu DC; Smesny S; Stanley JA; Stone JM; Szulc A; Taylor R; Thakkar K; Théberge J; Tibbo PG; van Amelsvoort T; Walecki J; Williamson PC; Wood SJ; Xin L; Yamasue H
JAMA Psychiatry; 2021 Jun; 78(6):667-681. PubMed ID: 33881460
[TBL] [Abstract][Full Text] [Related]
6. Extensive gray matter volume reduction in treatment-resistant schizophrenia.
Anderson VM; Goldstein ME; Kydd RR; Russell BR
Int J Neuropsychopharmacol; 2015 Feb; 18(7):pyv016. PubMed ID: 25716781
[TBL] [Abstract][Full Text] [Related]
7. Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders?
Anderson VM; McIlwain ME; Kydd RR; Russell BR
Psychiatry Res; 2015 Dec; 230(3):811-8. PubMed ID: 26564550
[TBL] [Abstract][Full Text] [Related]
8. Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive.
Mouchlianitis E; Bloomfield MA; Law V; Beck K; Selvaraj S; Rasquinha N; Waldman A; Turkheimer FE; Egerton A; Stone J; Howes OD
Schizophr Bull; 2016 May; 42(3):744-52. PubMed ID: 26683625
[TBL] [Abstract][Full Text] [Related]
9. Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia.
McQueen G; Sendt KV; Gillespie A; Avila A; Lally J; Vallianatou K; Chang N; Ferreira D; Borgan F; Howes OD; Barker GJ; Lythgoe DJ; Stone JM; McGuire P; MacCabe JH; Egerton A
Schizophr Bull; 2021 Apr; 47(3):662-671. PubMed ID: 33398325
[TBL] [Abstract][Full Text] [Related]
10. Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment.
Yamamori H; Hashimoto R; Fujita Y; Numata S; Yasuda Y; Fujimoto M; Ohi K; Umeda-Yano S; Ito A; Ohmori T; Hashimoto K; Takeda M
Neurosci Lett; 2014 Oct; 582():93-8. PubMed ID: 25218715
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: A meta-analysis.
Bartoli F; Crocamo C; Di Brita C; Esposito G; Tabacchi TI; Verrengia E; Clerici M; Carrà G
J Psychiatr Res; 2019 Jan; 108():24-33. PubMed ID: 30447508
[TBL] [Abstract][Full Text] [Related]
12. Association between serum levels of glutamate and neurotrophic factors and response to clozapine treatment.
Krivoy A; Hochman E; Sendt KV; Hollander S; Vilner Y; Selakovic M; Weizman A; Taler M
Schizophr Res; 2018 Feb; 192():226-231. PubMed ID: 28599751
[TBL] [Abstract][Full Text] [Related]
13. Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia.
Qurashi I; Collins JD; Chaudhry IB; Husain N
J Psychopharmacol; 2014 Jul; 28(7):707-8. PubMed ID: 24646811
[TBL] [Abstract][Full Text] [Related]
14. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study.
Tarumi R; Tsugawa S; Noda Y; Plitman E; Honda S; Matsushita K; Chavez S; Sawada K; Wada M; Matsui M; Fujii S; Miyazaki T; Chakravarty MM; Uchida H; Remington G; Graff-Guerrero A; Mimura M; Nakajima S
Neuropsychopharmacology; 2020 Mar; 45(4):632-640. PubMed ID: 31842203
[TBL] [Abstract][Full Text] [Related]
15. Gamma-aminobutyric acid (GABA) levels in the midcingulate cortex and clozapine response in patients with treatment-resistant schizophrenia: A proton magnetic resonance spectroscopy (
Ueno F; Nakajima S; Iwata Y; Honda S; Torres-Carmona E; Mar W; Tsugawa S; Truong P; Plitman E; Noda Y; Mimura M; Sailasuta N; Mikkelsen M; Edden RAE; De Luca V; Remington G; Gerretsen P; Graff-Guerrero A
Psychiatry Clin Neurosci; 2022 Nov; 76(11):587-594. PubMed ID: 36111425
[TBL] [Abstract][Full Text] [Related]
16. Frontostriatal functional connectivity and striatal dopamine synthesis capacity in schizophrenia in terms of antipsychotic responsiveness: an [
Kim S; Jung WH; Howes OD; Veronese M; Turkheimer FE; Lee YS; Lee JS; Kim E; Kwon JS
Psychol Med; 2019 Nov; 49(15):2533-2542. PubMed ID: 30460891
[TBL] [Abstract][Full Text] [Related]
17. [Retrospective study of clozapine use in Ile-de-France].
Hiltgen S; Mantelet S; Pinabel F; Enjaume F
Encephale; 2006 Oct; 32(5 Pt 1):688-96. PubMed ID: 17099592
[TBL] [Abstract][Full Text] [Related]
18. The effect of clozapine on neuroimaging findings in schizophrenia.
Ertugrul A; Uluğ B
Psychiatr Danub; 2007 Dec; 19(4):367-9. PubMed ID: 18000491
[TBL] [Abstract][Full Text] [Related]
19. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy.
Kegeles LS; Mao X; Stanford AD; Girgis R; Ojeil N; Xu X; Gil R; Slifstein M; Abi-Dargham A; Lisanby SH; Shungu DC
Arch Gen Psychiatry; 2012 May; 69(5):449-59. PubMed ID: 22213769
[TBL] [Abstract][Full Text] [Related]
20. Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels.
Ochi R; Plitman E; Patel R; Tarumi R; Iwata Y; Tsugawa S; Kim J; Honda S; Noda Y; Uchida H; Devenyi GA; Mimura M; Graff-Guerrero A; Chakravarty MM; Nakajima S
J Psychiatry Neurosci; 2022; 47(1):E1-E10. PubMed ID: 35027443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
